Targeting CRM1-HMGB1 Nuclear Translocation in Type 2 Diabetes-Driven Metabolic Dysfunction Associated Steatotic Liver Disease
Prabu Paramasivam, Gabriela Martinez Bravo, Brittany B. Coffman, Jaya Rajaiya, Satdarshan P. Monga, Roberto Ivan Mota
This study investigates the role of CRM1/HMGB1 nuclear translocation in T2D-driven MASLD and shows that inhibiting this pathway reduces HMGB1 release in T2D-NASH.
bioRxiv · Apr 9, 2025 · PreprintPathology